Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3559758 | 0.99 | GAA (0.53) | GAAHIF1AMEN1POLBKMT2A | |
| SCHEMBL3555469 | 0.89 | HIF1A (0.56) | GAAHIF1AMEN1POLBKMT2A | |
| SCHEMBL3557167 | 0.88 | HIF1A (0.54) | GAAHIF1AMEN1POLBKMT2A | |
| SCHEMBL3552433 | 0.81 | ALDH1A1 (0.54) | GAAHIF1AMEN1POLBKMT2A | |
| SCHEMBL3562415 | 0.79 | HCAR2 (0.59) | GAAHIF1AMEN1POLBKMT2A | |
| SCHEMBL3557253 | 0.79 | ALDH1A1 (0.57) | KMT2ASMN1; SMN2LMNAMAPTTSHR | |
| SCHEMBL3554671 | 0.79 | ALDH1A1 (0.62) | GAAMEN1POLBKMT2ASMN1; SMN2 | |
| SCHEMBL3552451 | 0.78 | ALDH1A1 (0.51) | GAAMEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL3552623 | 0.77 | TSHR (0.53) | GAAMEN1POLBKMT2ALMNA | |
| SCHEMBL3556557 | 0.76 | TP53 (0.55) | POLBSMN1; SMN2LMNAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101268063-B | Thiophene derivatives for the treatment of diabetes | HOFFMANN LA ROCHE | 2012-02-29 | — | — | CN | disclosed |
| US-7732452-B2 | Thiophene derivatives which are HM74A agonists | HOFFMANN-LA ROCHE INC. (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1931651-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| US-20070161650-A1 | Novel thiophene derivatives which are HM74A agonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-12 | — | — | US | disclosed |
| WO-2007039482-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072873-A1 | Novel thiophene derivatives which are HM74A agonists | HOFFMANN-LA ROCHE INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072873-A1 | Novel thiophene derivatives which are HM74A agonists | GPR84, GPR174, MRGPRX1 | GAA 3797/4885HIF1A 1691/4885MEN1 1943/4885 |
| US-20070161650-A1 | Novel thiophene derivatives which are HM74A agonists | GPR84, GPR174, MRGPRX1 | GAA 3797/4885HIF1A 1691/4885MEN1 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.